LeonaBio presented data on lasofoxifene research at AACR26

LeonaBio (LONA) attended the American Association for Cancer Research Annual Meeting 2026, AACR26, where independent researchers at Virginia Commonwealth University’s Massey Comprehensive Cancer Center presented nonclinical data on lasofoxifene, including its potential for a bone protective role in metastatic breast cancer. “We are delighted to learn the findings of this independent research at AACR26, attended by an audience of the world’s leading oncology researchers. We believe these data add to the body of evidence in support of lasofoxifene as a therapeutic candidate and align with the scientific rationale for LeonaBio’s ongoing ELAINE-3 Phase 3 evaluation of lasofoxifene in metastatic estrogen receptor (ER)-positive breast cancer in patients with ESR1 mutations. The potential ability to combine robust anti-tumor activity with beneficial estrogenic activity in bone tissue has been a core tenant of lasofoxifene’s development in breast cancer,” said David Portman, M.D., a consultant to LeonaBio.